Valuation: Alector, Inc.

Market Cap 170M 149M 138M 127M 239M 16.39B 243M 1.65B 644M 8.02B 638M 624M 27.71B P/E 2026 *
-1.79x
P/E 2027 * -2.39x
Enterprise Value -77.27M -67.7M -62.85M -57.75M -109M -7.46B -110M -749M -293M -3.65B -290M -284M -12.6B EV / Sales 2026 *
-11.3x
EV / Sales 2027 * -6.84x
Free-Float
86.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-0.65%
1 week+2.00%
Current month-23.88%
1 month-14.04%
3 months-37.55%
6 months-20.31%
Current year-1.92%
1 week 1.42
Extreme 1.415
1.55
1 month 1.37
Extreme 1.37
2.14
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
35.14
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 2013-04-30
Director of Finance/CFO 52 2025-06-19
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 72 2024-03-18
Chairman 77 2023-06-12
Director/Board Member 72 2018-09-30
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Free

Controller/Auditor

20,000 0.0180%
6/17/26 Free

Director

38,150 0.0344%
6/17/26 Free

Director

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
-0.65%+2.00%-11.05%-77.10% 171M
-0.43%-4.26%+52.09%+85.69% 55.57B
-0.24%+1.04%+55.76%+54.21% 54.26B
-0.54%-0.17%-17.60%-15.43% 23.35B
-1.82%-2.89%+3.61%+405.88% 23.54B
+0.05%-1.77%+38.71%-4.57% 20.32B
+3.16%+0.79%+37.98%-31.36% 17.36B
+1.08%-3.63%+36.77%+593.96% 15.59B
+0.43%-10.61%+175.63%+299.61% 14.96B
-2.03%-1.03%+23.63%+179.23% 14.11B
Average -0.10%-0.44%+39.56%+149.01% 23.92B
Weighted average by Cap. -0.18%-0.44%+44.19%+135.94%

Financials

2026 *2027 *
Net sales 6.86M 6.01M 5.58M 5.13M 9.66M 662M 9.8M 66.44M 26.01M 324M 25.74M 25.19M 1.12B 22.88M 20.05M 18.61M 17.1M 32.23M 2.21B 32.7M 222M 86.78M 1.08B 85.89M 84.04M 3.73B
Net income -94.11M -82.46M -76.55M -70.34M -133M -9.08B -135M -912M -357M -4.44B -353M -346M -15.35B -96.62M -84.65M -78.59M -72.22M -136M -9.32B -138M -936M -366M -4.56B -363M -355M -15.76B
Net Debt -247M -217M -201M -185M -348M -23.85B -353M -2.39B -937M -11.67B -928M -908M -40.31B -326M -286M -265M -244M -460M -31.49B -466M -3.16B -1.24B -15.41B -1.23B -1.2B -53.23B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-07-22 $1.530 -0.65% 333,340
26-07-21 $1.540 +7.69% 499,661
26-07-20 $1.430 -4.67% 463,910
26-07-17 $1.500 +2.04% 500,157
26-07-16 $1.470 -2.00% 713,579
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.530USD
Average target price
3.100USD
Spread / Average Target
+102.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock